Clinical outcomes of major clinical events and emergency triheptanoin use in critically ill patients with long-chain fatty acid oxidation disorders

被引：0
|
作者：
Enns, Gregory [1 ]
Marsden, Deborah [2 ]
Ramirez, Antonio Nino [2 ]
Bedrosian, Camille [2 ]
Reineking, Bridget [2 ]
Lu, Xiaoxiao [2 ]
Rahman, Syeda [2 ]
Vockley, Jerry [3 ]
机构：
[1] Stanford Univ, Stanford, CA 94305 USA
[2] Ultragenyx Pharmaceut Inc, Novato, CA USA
[3] Univ Pittsburgh, Pittsburgh, PA USA
来源：
MOLECULAR GENETICS AND METABOLISM | 2021年 / 132卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
eP130
引用
收藏
页码：S86 / S87
页数：3
相关论文
共 50 条
  • [41] Long-chain fatty acid oxidation disorders gene panel: clinical findings from a sponsored genetic testing program
    Miller, Vanessa Rangel
    Chettiath, Tobin
    Johnson, Britt
    Marsden, Deborah
    McKnight, Dianalee A.
    Sarafrazi, Sue
    Sommerville, Richard
    Willcock, Andrew
    Miller, Nicole
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 : S112 - S113
  • [42] Clinical manifestations, healthcare resource utilization, and costs among patients with long-chain fatty acid oxidation disorders: a retrospective claims database analysis
    Yang, Erru
    Fang, Zhenzhen
    Tan, Ruixin
    Guo, Yun
    He, Siyi
    Kruger, Eliza
    Nedzesky, Justin
    Marsden, Deborah
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (11) : 1893 - 1906
  • [43] Recombinant Activated Factor VII Use in Critically Ill Patients: Clinical Outcomes and Thromboembolic Events
    Brophy, Gretchen M.
    Candeloro, Christina L.
    Robles, Jaime R.
    Brophy, Donald F.
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (04) : 447 - 454
  • [44] Different Lipid Signature in Fibroblasts of Long-Chain Fatty Acid Oxidation Disorders
    Alatibi, Khaled I.
    Hagenbuchner, Judith
    Wehbe, Zeinab
    Karall, Daniela
    Ausserlechner, Michael J.
    Vockley, Jerry
    Spiekerkoetter, Ute
    Gruenert, Sarah C.
    Tucci, Sara
    CELLS, 2021, 10 (05)
  • [45] MAJOR CLINICAL MANIFESTATIONS AND EVENTS AMONG PATIENTS WITH LONG-CHAIN FATTY ACID OXIDATION DISORDERS (LC-FAOD) IN THE UNITED STATES: REAL-WORLD RESULTS FROM LC-FAOD ODYSSEY
    Yang, E.
    Kruger, E.
    Deering, K.
    Stubbe, C.
    Mace, K.
    Tierney, M.
    Cibelli, E.
    Drozd, D.
    Ross, N.
    Herout, P.
    Shillington, A.
    Thomas, N. A.
    Marsden, D.
    Kritzer, A.
    VALUE IN HEALTH, 2022, 25 (07) : S311 - S312
  • [46] QUALITATIVE EXPLORATION OF THE PATIENT EXPERIENCE OF LONG-CHAIN FATTY ACID OXIDATION DISORDERS
    Hall, R.
    Kruger, E.
    Bowden, A.
    Cimms, T.
    Skrinar, A.
    Tinsley, K.
    Gater, A.
    VALUE IN HEALTH, 2020, 23 : S342 - S343
  • [47] Long-Chain Polyunsaturated Fatty Acids and Clinical Outcomes of Preterm Infants
    Lapillonne, Alexandre
    Moltu, Sissel J.
    ANNALS OF NUTRITION AND METABOLISM, 2016, 69 : 36 - 44
  • [48] Concerning "Triheptanoin vs trioctanoin for long-chain fatty acid oxidation disorders: A double blinded, randomized controlled trial" by Gillingham et al.
    Shoffner, John M.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2019, 42 (03) : 394 - 395
  • [49] Association of delayed time in the emergency department with the clinical outcomes for critically ill patients
    Lin, S.
    Ge, S.
    He, W.
    Zeng, M.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2021, 114 (05) : 311 - 317
  • [50] Long-Chain Fatty Acid Oxidation Disorders: Managed Care and Specialty Pharmacy Implications
    Pannier, Alan
    AMERICAN JOURNAL OF MANAGED CARE, 2020, 26 (07): : S155 - S161
12345